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Castleman’s disease is also known as angiofollicular lymphoid
hyperplasia, giant lymph node hyperplasia, lymphoid ha-
martoma, and follicular lymphoreticuloma. It is a rare disease,
characterized by hypertrophy of the lymph nodes and his-
tologically by angiofollicular lymph node hyperplasia.
Benjamin Castleman and his colleagues first mentioned it in
1956, in a group of patients with localized mediastinal lymph
node hyperplasia.1,2 Since then, more than 400 cases have been
reported in the international literature.
Case report
A 34-year-old woman presented with symptoms of upper
respiratory tract infection and acute gastroenteritis. She had
no history of altered bowel habits prior to this admission but
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tumour embolization was planned before excision. Mesenteric arteriogram revealed that the feeder arteries arose
from the superior mesenteric artery and embolization was aborted for fear of causing bowel ischaemia. On
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tomography appearance of hypervascularity. The tumour with the mesentery and the overlying segment of
jejunum was excised completely. Histopathology confirmed Castleman’s disease. The purpose of this report is to
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admitted to a recurrent right iliac fossa pain and weight loss
over a period of 6 months. There was no history of note. On
examination, she was afebrile with a pulse rate of 80/minute
and blood pressure of 110/70 mmHg. She was pale and had
clubbed fingers. Cervical lymph nodes were not palpable.
Abdominal palpation revealed a firm and slightly tender mass
over the right iliac fossa. This mass measured about 5 cm and
moved with respiration. The liver and spleen were palpable
5 cm below the costal margin but were non-tender. Otherwise,
the systemic examination was unremarkable.
Her haemoglobin was 5.6 g/dL, leukocyte count was
10,200/mm3, and platelet count was elevated at 625,000/mm3.
The erythrocyte sedimentation rate was elevated to 145 mm/hr.
Full blood analysis revealed microcytic hypochromic anaemia,
but haemoglobin electrophoresis did not show any haemo-
globinopathies. Liver function tests showed hypoalbumi-
naemia (21 g/L) but normal levels of bilirubin and trans-
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aminases. Her renal function and coagulation profile were
within normal limits.
Chest radiography showed normal cardiac size with
normal lung markings. Ultrasound showed a mass in the
right iliac fossa, with a moderately enlarged liver and spleen.
Duplex ultrasound showed that the mass was hypervascular.
Computerized tomography (CT) scan confirmed a right iliac
fossa mass measuring 5 x 5 cm with internal calcification
(Figure 1). The mass was not enhanced by contrast agent and
was not related to the bowel. There was streakiness of the
mesentery with inter-loop fluid collection, indicating an
inflammatory reaction. The para-aortic nodes were also
enlarged. The liver and spleen did not show any focal lesions.
Our provisional diagnosis was a soft tissue sarcoma; a
visceral angiogram with preoperative tumour embolization
was planned. Mesenteric arteriogram showed that the arterial
supply was mainly from the superior mesenteric artery and
had prominent venous drainage (Figure 2). Blood was also
supplied by the lumbar arteries. Tumour embolization was
not performed for fear of causing bowel ischaemia.
We proceeded to a laparotomy. Intraoperatively, we noted
incidental malrotation of the bowel with a short mesentery
and mobile caecum and ascending and descending colons.
The hepatic and splenic flexural attachments were absent. The
right iliac fossa mass appeared to be encapsulated and was
enclosed within the leaves of the jejunal mesentery, about
20 cm from the duodenojejunal flexure. The mass was lobulated
and comprised of multiple enlarged and matted lymph nodes,
the largest measuring 4 cm (Figure 3). There were multiple tiny
lymph node-like nodules studded in the mesentery. The mass,
together with the enclosing mesentery, was resected along
with 15 cm of jejunum, and an end-to-end anastomosis of the
bowel was created. Postoperative recovery was uneventful.
Histopathology showed localized plasma cell Castleman’s
disease. The patient was advised to return for lifelong follow-
up with periodic ultrasound examination of the abdomen for
possible tumour recurrence.
Discussion
Castleman’s disease is classified into two types: localized, in
Figure 3. Intraoperative findings reveal the lobulated mass, after
ligation of its blood supply, along with the jejunum and its mesentery.
Figure 1. Preoperative computerized tomography scan of the
abdomen shows the right iliac fossa mass.
Figure 2. Mesenteric angiogram reveals that the main blood supply
to the mass is the superior mesenteric artery.
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which the disease is situated at one site only, and multicentric
or systemic, in which several sites are involved.2,3 Histologically,
there are two main types of Castleman’s disease, hyaline vascu-
lar and plasma cell.2–5 Hyaline vascular Castleman’s disease is
much more common (90%) than plasma cell disease.2 Multiple
germinal centres, surrounded by circumferentially arranged
layers (onion skin pattern) of small lymphocytes, with a
prominent vascular stroma and occasional plasma cells,
characterize hyaline vascular disease. Sheets of dense plasma
cells and a less vascular stroma surrounding the germinal
centres characterize plasma cell disease.3
Patients with hyaline vascular Castleman’s disease are
usually asymptomatic and the lesion tends to be localized.2
Patients are usually young adults, less than 35 years old.3 The
lesion is often discovered incidentally, for example, on routine
pre-employment chest radiography. Sometimes, when the
lesion is large and compresses adjacent structures, the patient
presents with abdominal or thoracic pain. The more common
sites are the mediastinum, abdomen, and pelvis.3 Most patients
with plasma cell Castleman’s disease present with consti-
tutional signs and symptoms of fever, malaise, anaemia,
thrombocytosis, and increased erythrocyte sedimentation rate
caused by B-cell hyper-reactivity.2 Only 10% of these patients
have localized disease.3
Multicentric Castleman’s disease (MCD) is a severe form of
the disease. Patients are usually older, in their fifth or sixth
decades of life, with multiple lymph-node involvement and
associated hepatosplenomegaly.3,6 Some patients have POEMS
syndrome, which consists of peripheral neuropathy, organo-
megaly, endocrinopathy, monoclonal gammopathy, and skin
lesions.7,8 Histologically, MCD may present as a combination
of both hyaline vascular and plasma cell morphology.3 Medi-
cal opinions differ as to whether MCD is a distinct type or a
disseminated variant of a localized disease.4–6
Castleman’s disease is associated with paraneoplastic
pemphigus (an autoimmune bullous mucocutaneous
disorder), benign lesions such as pseudotumour, and
malignancies such as lymphoma and Kaposi’s sarcoma.9–14
The aetiology of Castleman’s disease is not well understood.
Viral infection by human herpes virus 8 or Epstein-Barr virus,
and dysregulation of interleukin-6 (IL-6) secretion have been
implicated as possible causal factors of this disease. No genetic
or toxic factor has thus far been identified.15–17
Differential diagnosis of this rare disease includes reactive
lymph node hyperplasia, malignant lymphoma, HIV infection,
and autoimmune diseases such as rheumatoid disease or
Sjögren’s syndrome. It is therefore important to obtain proper
clinical, histological, and immunohistochemical analysis. The
diagnosis of Castleman’s disease is based on histological ex-
amination of the specimen in combination with immunohis-
tochemical labelling.18,19
The treatment of choice for localized Castleman’s disease
is complete surgical resection.2,3,20 There is a low recurrence
rate with subtotal resection. The prognosis is very good with
no relapse in almost all cases if the lesion is completely removed.3
Radiotherapy is an alternative option if the patient is a poor
surgical candidate, but the result varies.3,20 Long-term follow-
up is required to detect the possible development of malignancy,
such as non-Hodgkin’s lymphoma.14 The treatment of MCD
involves surgery, radiotherapy, steroids, and combination
chemotherapy, such as cyclophosphamide, vincristine, and
doxorubicin.3,4,20,21 Other treatment modalities include
interferon-α, retinoic acid, and anti-IL-6 antibodies.3,22,23
However, the prognosis is currently still poor for this type of
disease, with a reported median survival of only 26 months.4
The disease in our patient was confined to one site only, in
a small area of the jejunal mesentery. Histopathological and
immunohistochemical staining showed plasma cell Castle-
man’s disease. The prognosis for this patient with localized
Castleman’s disease is favourable as the lesion was completely
resected and the patient is currently asymptomatic with no
disease recurrence more than 1 year after the operation.
Abdominal CT scan showed a mass that was not enhanced
by contrast agent, indicating that it might not be a vascular
lesion. This contradicted the initial duplex ultrasound finding
of a hypervascular mass, which was interesting because the
tumour had arisen from within the two leaves of the mesentery.
Retrospectively, the duplex ultrasound scan finding of hyper-
vascularity was believed to be due to the mesenteric vessels
coursing the surface of the tumour.
This rare and interesting tumour caused a diagnostic
dilemma due to the discrepancy between findings on duplex
ultrasound and CT scan. Mesenteric angiogram revealed that
the feeder artery arose from the superior mesenteric artery,
which further confused the picture. This tumour was uniquely
wrapped by the leaves of the mesentery, which accounted for
the investigative findings. This had not been previously
described in the literature.
In conclusion, Castleman’s disease is a rare non-neoplastic
lymphoproliferative disorder that relies on proper clinical and
histological evaluation for its diagnosis. Other more common
diseases such as lymphoma and autoimmune diseases must be
ruled out. Localized Castleman’s disease has a very good
prognosis with a complete cure by total surgical resection.
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MCD, on the other hand, still has a poor outcome despite the
availability of multiple modalities of therapy.
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